triumph-1 trial retatrutide 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 New Phase 3 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most 15 month update Triumph-1(retatrutide obesity

Its much easier

15 These studies demonstrate that GLP-1 agonists are a potential alternative for patients with obesity or T2DM who develop psoriasis and are resistant to biologic therapies

But researchers are also studying the drugs effects on broader metabolic health, including blood sugar regulation, cholesterol levels and cardiovascular risk markers

Normoglycemics patients affected by asymptomatic significant carotid artery stenosis at 2 years of Follow-Up: role of microRNAs Modulation: the ATIMIR Study

Eli Lilly plans to begin orforgliprons review process for regulatory approval for weight loss in 2025 and for type 2 diabetes in 2026